G
George Risi
Publications - 7
Citations - 281
George Risi is an academic researcher. The author has contributed to research in topics: AS03 & Vaccination. The author has an hindex of 5, co-authored 6 publications receiving 274 citations.
Papers
More filters
Journal ArticleDOI
Safety and Cross-Reactive Immunogenicity of Candidate AS03-Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults
Joanne M. Langley,Louise Frenette,Linda Ferguson,Dennis Riff,Eric Sheldon,George Risi,Casey Johnson,Ping Li,Richard Kenney,Bruce L. Innis,Louis Fries +10 more
TL;DR: The AS03-adjuvanted A/Indonesia/05/2005 (NIBRG-14) vaccines were significantly more immunogenic than nonadjuVanted vaccine in homologous assays and fulfilled European and US licensure criteria for immunogenicity for influenza vaccines.
Journal ArticleDOI
Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study
Joanne M. Langley,George Risi,Michael Caldwell,Larry Gilderman,Bruce Berwald,Charles Fogarty,Terry Poling,Dennis Riff,Mira Baron,Louise Frenette,Eric Sheldon,Harry Collins,Marc Shepard,Marc Dionne,Daniel Brune,Linda Ferguson,David W. Vaughn,Ping Li,Louis Fries +18 more
TL;DR: In adults and elderly adults, AS03A-adjuvanted H5N1 candidate vaccine was highly immunogenic for A/Indonesia/05/2005, with cross-reactivity against A/Vietnam/1194/2004.
Journal ArticleDOI
Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant
Murdo Ferguson,George Risi,Matthew Davis,Eric Sheldon,Mira Baron,Ping Li,Miguel Madariaga,Louis Fries,Olivier Godeaux,David W. Vaughn +9 more
TL;DR: A single dose of the 3.75-μg HA AS03(A)-adjuvanted H1N1 2009 influenza vaccine was highly immunogenic in both age strata (18-64 and >64 years), inducing long-term persistence of the immune response until at least 6 months after dose 1.
Journal ArticleDOI
Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age.
TL;DR: The ChimeriVax-WN02 vaccine was highly immunogenic and well tolerated among subjects ≥ 50 years old at all dose levels and showed no dose relationship.
Journal ArticleDOI
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months.
George Risi,Louise Frenette,Joanne M. Langley,Ping Li,Dennis Riff,Eric Sheldon,David W. Vaughn,Louis Fries +7 more
TL;DR: Although superior immunogenicity of AS03-adjuvanted compared to unadjuVanted priming was not demonstrated, higher antibody titres which persisted longer were seen when both priming and boosting regimens were adjuvanted, which may affect duration of response or heterologous immunity.